Figure 2.
Hematopoietic populations in homozygous NrasG12D,C181Smice. (A-B) Immunophenotyping of splenocytes showing the frequencies of differentiated cells (A; n = 4) and myeloid progenitors (B; n = 5). (C-E) Immunophenotyping of BM subpopulations (n = 5) showing numbers of differentiated cells (C), myeloid progenitors (D), and immature HSPCs (E). The number of cells per femur was calculated by multiplying the frequency of each population by the total femur cell count. (F-G) Cell-cycle analysis in HSPCs (n = 3). The gating strategy for LKS and LKS-SLAM populations and the average values in LKS cells, LKS subsets, and multipotent progenitors (CD48− CD150− LKS cells), respectively. The LKS-SLAM population is composed of CD48− CD150+ LKS cells. *P < .05; **P < .1; ***P < .001. Data are average ± SEM. CMP, common myeloid progenitor; GMP, granulocyte-macrophage progenitor; MEP, megakaryocytic-erythroid progenitor.

Hematopoietic populations in homozygous NrasG12D,C181Smice. (A-B) Immunophenotyping of splenocytes showing the frequencies of differentiated cells (A; n = 4) and myeloid progenitors (B; n = 5). (C-E) Immunophenotyping of BM subpopulations (n = 5) showing numbers of differentiated cells (C), myeloid progenitors (D), and immature HSPCs (E). The number of cells per femur was calculated by multiplying the frequency of each population by the total femur cell count. (F-G) Cell-cycle analysis in HSPCs (n = 3). The gating strategy for LKS and LKS-SLAM populations and the average values in LKS cells, LKS subsets, and multipotent progenitors (CD48 CD150 LKS cells), respectively. The LKS-SLAM population is composed of CD48 CD150+ LKS cells. *P < .05; **P < .1; ***P < .001. Data are average ± SEM. CMP, common myeloid progenitor; GMP, granulocyte-macrophage progenitor; MEP, megakaryocytic-erythroid progenitor.

Close Modal

or Create an Account

Close Modal
Close Modal